ReShape Lifesciences Inc., a leader in physician-led weight loss and metabolic health solutions, has announced the pricing of a public offering of 1,054,604 shares of common stock at $2.50 per share, aiming to raise approximately $2.6 million. The offering, expected to close on June 9, 2025, is conducted under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission $(SEC.UK)$. Maxim Group LLC is serving as the sole placement agent for the offering. Details of the offering are available in a preliminary prospectus supplement filed with the SEC, with final terms to be disclosed in an upcoming final prospectus supplement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.